网红黑料

Skip to main content
(352) 733-0111

ATA-200 gene therapy trial in patients with LGMDR5

  • Status
    Accepting Candidates
  • Age
    6 Years - 13 Years
  • Sexes
    All
  • 网红黑料y Volunteers
    No
I'm interested
Share this study

Objective

The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5). Patients will be treated sequentially in 2 dose-cohorts.

Description

This is a multicenter Phase 1b assessing the safety and tolerability of 2 doses of ATA-200 for the treatment of LGMDR5.

The dose escalation phase will enroll ambulant patients with LGMDR5. Two dose cohorts (C1) and (C2) will be enrolled sequentially and enrollment will be staggered with at least 4-week interval between 2 patient treatments. An initial cohort C1 of three (3) patients will receive a potentially effective dose corresponding to the minimum effective dose (MED) in preclinical studies.

Enrollment of three (3) patients in the 2nd higher dose cohort C2 (with a 7-fold safety margin relative to the highest safe dose in the GLP toxicology study) will be initiated following review of the one-month safety data post-administration in cohort C1 by an independent Data Safety Monitoring Board (DSMB).

Time point of primary interest for safety evaluation and dose selection for future studies is at 6 months.

All subjects will be followed up for an additional 4.5 years after completion of the evaluation period.

Details

Full study title A Phase 1-2, open-label, dose escalation study to evaluate the safety of 2 doses of intravenous ATA-200, an adeno-associated viral vector carrying the human gamma-sarcoglycan gene, in patients with gamma-sarcoglycanopathy (limb-girdle muscular dystrophy LGMDR5, formerly LGMD2C).
Protocol number OCR46440
ClinicalTrials.gov ID NCT05973630
Phase Phase 1/Phase 2

Eligibility

Inclusion Criteria:

  • Confirmed diagnosis of LGMDR5 before age of 10, based on clinical presentation and genotyping

  • Ambulant male or female patients aged 6 to less than 12 years of age at screening

  • Able to perform the 10-meter walk test (10MWT) in less than 15 sec and to rise from chair with or without arm support

Exclusion Criteria:

  • Detectable neutralizing antibodies against AAV8

  • Cardiomyopathy with left ventricular ejection fraction (LVEF) < 50%

  • Respiratory assistance

  • Concomitant medical condition that might interfere with LGMDR5 evolution

  • Acute illness within 4 weeks of anticipated IMP administration

  • Current participation in another clinical trial with investigational medicinal product

  • Previous participation in gene and cell therapy trials

  • Any condition that would contraindicate immunosuppressant treatment

  • Presence of any permanent items (e.g., metal braces) precluding undergoing MRI

  • Any vaccination 1 month prior to planned IMP administration

  • Serology consistent with HIV exposure or active hepatitis B or C infection

  • Grade 2 or higher lab abnormalities for liver function tests, creatinine, hemogram and coagulation

Lead researcher

Participate in a study

Here are some general steps to consider when participating in a research study:

  1. Step
    1

    Contact the research team

    Call or email the research team listed within the specific clinical trial or study to let them know that you're interested. A member of the research team, such as the researcher or study coordinator, will be available to tell you more about the study and to answer any questions or concerns you may have.

    Primary contact

  2. Step
    2

    Get screened to confirm eligibility

    You may be asked to take part in prescreening to make sure you are eligible for a study. The prescreening process ensures it is safe for you to participate. During the prescreening process, you will be asked some questions and you may also be asked to schedule tests or procedures to confirm your eligibility.

  3. Step
    3

    Provide your consent to participate

    If you are eligible and want to join the clinical trial or study, a member of the research team will ask for your consent to participate. To give consent, you will be asked to read and sign a consent form for the study. This consent form explains the study's purpose, procedures, risks, benefits and provides other important information, such as the study team's contact information.

  4. Step
    4

    Participate

    If you decide to participate in a clinical trial or study, the research team will keep you informed of the study requirements and what you will need to do to throughout the study. For some trials or studies, your health care provider may work with the research team to ensure there are no conflicts with other medications or treatments.